BioSpace News Archive

Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. announced that on June 2, 2023, it completed a private placement of 22,000,000 class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares for US$4.4 million.

Novarad, a leading medical technology company, is delighted to announce the groundbreaking success of a bilateral sacroiliac joint fusion surgery performed by Dr. Harmantya at Tangerang Hospital, an EMC Hospital, in Indonesia.

Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, announced the promotion of Dr. Shengfang Jin to President and Chief Executive Officer, effective immediately.

Servier today presented updated efficacy and safety data from the global Phase 3 AGILE study of TIBSOVO® (ivosidenib tablets) in combination with the chemotherapy azacitidine for newly-diagnosed acute myeloid leukemia (AML), and a new analysis of treatment response to TIBSOVO.

RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, has been awarded a national group purchasing agreement for the distribution of Radiopharmaceutical Products with Premier, Inc, a leading healthcare improvement company headquartered in Charlotte, North Carolina.

CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer® for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity

Varex Imaging Corporation announced that management is scheduled to present at the Jefferies Healthcare Conference.

Paragon operates an industry-leading geochemistry lab strategically located near Reno, Nevada, at the heart of one of the world’s most active mining regions

Mustard plant-based development programs to focus on soil and microbiome health, nutrient and water use efficiencies, and plant yields.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,